Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

142 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients.
Mertens LS, Claps F, Mayr R, Bostrom PJ, Shariat SF, Zwarthoff EC, Boormans JL, Abas C, van Leenders GJLH, Götz S, Hippe K, Bertz S, Neuzillet Y, Sanders J, Broeks A, Peters D, van der Heijden MS, Jewett MAS, Stöhr R, Zlotta AR, Eckstein M, Soorojebally Y, van der Schoot DKE, Wullich B, Burger M, Otto W, Radvanyi F, Sirab N, Pouessel D, van der Kwast TH, Hartmann A, Lotan Y, Allory Y, Zuiverloon TCM, van Rhijn BWG. Mertens LS, et al. Among authors: boormans jl. Urol Oncol. 2022 Mar;40(3):110.e1-110.e9. doi: 10.1016/j.urolonc.2021.10.010. Epub 2021 Dec 11. Urol Oncol. 2022. PMID: 34906411 Free article.
Short-term Changes in Health-related Quality of Life of Patients Undergoing Radical Surgery for Upper Urinary Tract Urothelial Carcinoma: Results from a Prospective Phase 2 Clinical Trial.
van Doeveren T, Remmers S, Atema V, van den Bergh RCN, Boevé ER, Cornel EB, van der Heijden AG, Hendricksen K, Cauberg ECC, Jacobs RAL, Kroon BK, Leliveld AM, Meijer RP, Merks B, Oddens JR, Roelofs L, Somford DM, de Vries P, Wijsman B, Windt WAKM, Zwaan PJ, van Leeuwen PJ, Boormans JL, Aben KKH. van Doeveren T, et al. Among authors: boormans jl. Eur Urol Open Sci. 2024 Jan 5;60:15-23. doi: 10.1016/j.euros.2023.12.005. eCollection 2024 Feb. Eur Urol Open Sci. 2024. PMID: 38375344 Free PMC article.
An activating mutation in AKT1 in human prostate cancer.
Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC. Boormans JL, et al. Int J Cancer. 2008 Dec 1;123(11):2725-6. doi: 10.1002/ijc.23787. Int J Cancer. 2008. PMID: 18798258 No abstract available.
E17K substitution in AKT1 in prostate cancer.
Boormans JL, Korsten H, Ziel-van der Made AC, van Leenders GJ, Verhagen PC, Trapman J. Boormans JL, et al. Br J Cancer. 2010 May 11;102(10):1491-4. doi: 10.1038/sj.bjc.6605673. Epub 2010 Apr 20. Br J Cancer. 2010. PMID: 20407443 Free PMC article.
No evidence of FGFR3 mutations in prostate cancer.
Zuiverloon TC, Boormans JL, Trapman J, van Leenders GJ, Zwarthoff EC. Zuiverloon TC, et al. Among authors: boormans jl. Prostate. 2011 May;71(6):637-41. doi: 10.1002/pros.21279. Epub 2010 Oct 18. Prostate. 2011. PMID: 20957671
142 results